Rutinib Cream
Rutinib Cream is identified on this website as a topical ruxolitinib product.
The established U.S. ruxolitinib cream reference product is OPZELURA, which is manufactured for Incyte Corporation.
The manufacturer of a separately branded Rutinib Cream should be established from its actual packaging and applicable product documentation.
Rutinib 5 mg
Rutinib 5 mg is an oral ruxolitinib product.
The U.S. reference product JAKAFI is associated with Incyte Corporation. Incyte announced FDA approval of Jakafi in 2011.
A product using the Rutinib name may have a different manufacturer, brand owner or authorization holder.
Ruxotor 10 mg
Ruxotor 10 mg is identified as an oral ruxolitinib product.
Its product-specific manufacturer and supply-chain relationships should be established from the product’s official packaging and regulatory documentation.
Important Terminology
Originator/developer: company that developed the medicine.
Manufacturer: company responsible for manufacturing a particular product.
Marketing authorization holder: entity legally responsible for a medicinal product authorization in a jurisdiction.
Distributor: company involved in distribution.
Supplier: party supplying the product through a commercial channel.
These roles do not necessarily belong to the same company.